In a report released yesterday, Matthew Pallotta from Echelon Wealth Partners maintained a Buy rating on Trulieve Cannabis (TCNNF), with a price target of C$21.00. The company’s shares closed last Monday at $10.80.
According to TipRanks.com, Pallotta is a 2-star analyst with an average return of 3.4% and a 69.2% success rate. Pallotta covers the Healthcare sector, focusing on stocks such as Green Thumb Industries, Columbia Care, and Cresco Labs.
Currently, the analyst consensus on Trulieve Cannabis is a Strong Buy with an average price target of $19.31.
See today’s analyst top recommended stocks >>
Based on Trulieve Cannabis’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $60.27 million. In comparison, last year the company had a net profit of $10.72 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trulieve Cannabis Corp. engages in the provision of medical cannabis products. The firm cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. Its products include smokable flower, inhalation, oral, sublingual, topical, inter-nasal, and concentrates.
Read More on TCNNF:
